First Choice Treatment
In most centers, plaque radiotherapy is the first choice of treatment for uveal melanoma. Ru-106 Eye Applicators require no assembly before use and have a half-life of 373.6 days which allows for multiple uses over a one- year period.
Ergonomic Design
Only 1 mm in thickness, Ru-106 plaques are easy to position on the globe. A selection of 13 different types enable dosimetry to be optimized according to tumor size and shape.
Beneficial Beta Radiation
The beta radiation emitted by Ru-106/Rh-106 has a limited range, providing a high dose to tumors up to 5 mm in thickness, while reducing the risk of collateral damage to optic disc and fovea.
Source Strength and Depth Dose Rate
Plaques come with an extensive individual source certificate, documenting the axial dose rate in 1 mm steps from the applicator surface including the reference dose rate at 2 mm distance.
First Choice Treatment
In most centers, plaque radiotherapy is the first choice of treatment for uveal melanoma. Ru-106 Eye Applicators require no assembly before use and have a half-life of 373.6 days which allows for multiple uses over a one- year period.
Ergonomic Design
Only 1 mm in thickness, Ru-106 plaques are easy to position on the globe. A selection of 13 different types enable dosimetry to be optimized according to tumor size and shape.
Beneficial Beta Radiation
The beta radiation emitted by Ru-106/Rh-106 has a limited range, providing a high dose to tumors up to 5 mm in thickness, while reducing the risk of collateral damage to optic disc and fovea.
Source Strength and Depth Dose Rate
Plaques come with an extensive individual source certificate, documenting the axial dose rate in 1 mm steps from the applicator surface including the reference dose rate at 2 mm distance.
